Literature DB >> 2784355

The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate.

N Lahat1, B Alexander, D R Levin, B Moskovitz.   

Abstract

Several immunological in vitro tests were performed on peripheral blood mononuclear cells of patients with adenocarcinoma of the prostate, stages A, B, C, D. The cytotoxicity of effector natural killer cells towards K-562 targets decreased with increasing disease spread, while their percentage was not significantly changed. The proportion of CD4 (helper/inducer) cells tended to fall with tumor advance, but the proportion of CD8 (suppressor/cytotoxic) cells remained almost constant. Secretion of interleukin-2 from peripheral blood mononuclear cells was diminished with disease progression. Pretreatment of a patient's lymphocytes with cimetidine (antagonist of H-2-bearing suppressor T cells) or indomethacin (inhibitor of prostaglandin synthesis) enhanced natural killer activity. Our data point to the existence of aberrant immune functions in early stages of carcinoma of the prostate and to aggravation of these immune abnormalities in advanced disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784355     DOI: 10.1007/bf00204990

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  35 in total

1.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

2.  In vitro effect of cimetidine on human cell-mediated cytotoxicity. I. Inhibition of natural killer cell activity.

Authors:  A Ruiz-Argüelles; K B Seroogy; R E Ritts
Journal:  Cell Immunol       Date:  1982-05-01       Impact factor: 4.868

3.  Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo.

Authors:  O Haller; M Hansson; R Kiessling; H Wigzell
Journal:  Nature       Date:  1977-12-15       Impact factor: 49.962

4.  The present status of radical prostatectomy for stages A and B prostatic cancer.

Authors:  H J Jewett
Journal:  Urol Clin North Am       Date:  1975-02       Impact factor: 2.241

5.  Interleukin 2 dependence of human natural killer (NK) cell activity.

Authors:  W Domzig; B M Stadler; R B Herberman
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

6.  Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon.

Authors:  P Flodgren; H O Sjögren
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Characterization of the human blood lymphocytes that produce a histamine-induced suppressor factor (HSF).

Authors:  R E Rocklin; J Breard; S Gupta; R A Good; K L Melmon
Journal:  Cell Immunol       Date:  1980-05       Impact factor: 4.868

8.  Suppressor cells in immunodepressed bladder and prostate cancer patients.

Authors:  H W Herr
Journal:  J Urol       Date:  1980-05       Impact factor: 7.450

9.  Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN-alpha(Le)] and cimetidine.

Authors:  P Flodgren; S Borgström; P E Jönsson; C Lindström; H O Sjögren
Journal:  Int J Cancer       Date:  1983-12-15       Impact factor: 7.396

10.  Inhibition of natural killer activity by tumor-associated lymphoid cells from ascites ovarian carcinomas.

Authors:  P Allavena; M Introna; C Mangioni; A Mantovani
Journal:  J Natl Cancer Inst       Date:  1981-08       Impact factor: 13.506

View more
  8 in total

1.  Ex vivo generation of highly purified and activated natural killer cells from human peripheral blood.

Authors:  Satoru Saito; Yui Harada; Yosuke Morodomi; Mitsuho Onimaru; Kumi Yoshida; Ryoichi Kyuragi; Hisahiro Matsubara; Yoshikazu Yonemitsu
Journal:  Hum Gene Ther Methods       Date:  2013-08       Impact factor: 2.396

2.  Interleukin-2-induced growth inhibition of prostatic adenocarcinoma (Dunning R3327) in rats.

Authors:  R Henriksson; A Widmark; A Bergh; J E Damber
Journal:  Urol Res       Date:  1992

3.  Comparison between NK cell activity and prostate cancer stage and grade in untreated patients: correlation with tumor markers and hormonal serotest data.

Authors:  M Tarle; I Kraljić; M Kastelan
Journal:  Urol Res       Date:  1993-01

Review 4.  Synergistic immunologic targets for the treatment of prostate cancer.

Authors:  Karen M Doersch; Kelvin A Moses; Warren E Zimmer
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-20

5.  The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation.

Authors:  S Johansson; M Landström; K Hellstrand; R Henriksson
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

6.  Correlation Between Natural Killer Cell Activity and Systemic Inflammatory Markers for Heterogeneous Cancer Patients Treated With Wheel Balance Cancer Therapy.

Authors:  Hwi-Joong Kang; Kyeore Bae; Jee-Hye Kim; Chong-Kwan Cho; Hwa-Seung Yoo
Journal:  Integr Cancer Ther       Date:  2017-07-17       Impact factor: 3.279

7.  Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy.

Authors:  Adriana C Vidal; Lauren E Howard; Emily Wiggins; Amanda M De Hoedt; Stephen L Shiao; Simon Knott; Emanuela Taioli; Jay H Fowke; Stephen J Freedland
Journal:  Cancer Epidemiol       Date:  2019-08-01       Impact factor: 2.984

8.  The clinical usefulness of natural killer cell activity in patients with suspected or diagnosed prostate cancer: an observational cross-sectional study.

Authors:  Wan Song; Ji Woong Yu; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi; Eun-Suk Kang; Hwang Gyun Jeon
Journal:  Onco Targets Ther       Date:  2018-07-06       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.